A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Anthony W. Tolcher,Jordan Berlin,Jan Cosaert,John S. Kauh,Emily Chan,Sarina Anne Piha-Paul,Alex Amaya,Shande Tang,Kyla Driscoll,Richard Kimbung,S. R.Prasad Kambhampati,Ivelina Gueorguieva,David S. Hong

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

2017

Anthony W. Tolcher
Jordan Berlin
Jan Cosaert
John S. Kauh
Emily Chan
Sarina Anne Piha-Paul
Alex Amaya
Shande Tang
Kyla Driscoll
Richard Kimbung
S. R.Prasad Kambhampati
Ivelina Gueorguieva
David S. Hong

Purpose LY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives were to assess safety and pharmacokinetics (PK).

Keywords:

Pharmacology
Immunology
Monoclonal antibody
Medicine
Receptor
Pharmacokinetics
receptor type
treatment resistance
pharmacology toxicology
phase i study
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations